Vaxcyte is a clinical-stage vaccine innovation company focused on developing next-generation vaccines to prevent and treat infectious diseases. They are currently advancing vaccines for invasive pneumococcal disease, Group A Strep, periodontal disease, and Shigella. Vaxcyte leverages its XpressCFTM platform, a cell-free protein synthesis platform, to design and produce vaccines in ways that are believed to be superior to conventional technologies. As a biotech company, Vaxcyte is impacting the global health landscape by developing superior vaccines and offering them to the world. They are currently in the process of creating cutting edge vaccines to help combat deadly infectious diseases. Their work environment is guided by core values such as Rethinking Convention, Aiming High, Leading with Heart, and Modeling Excellence. Vaxcyte’s cell-free protein synthesis platform enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. Vaxcyte has a current tech stack of SPF, Microsoft Exchange Online, Office 365 Mail, Cloudflare Hosting, Microsoft Azure DNS, Cloudflare DNS, WP Engine, Smartsheet, Box, and Dropbox Business, which aids them in their pursuit of creating the most complex biologics. The company's team currently consists of 101-250 employees. They are a public company that has secured funding through post-IPO equity offerings, totaling $3.847 billion in funding rounds. Vaxcyte's stock is publicly traded on the NASDAQ under the symbol PCVX. This role is eligible for relocation assistance.